Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells

L. C. J. te Boome; C. Mansilla; L. E. van der Wagen; C. A. Lindemans; E. J. Petersen; E. Spierings; K. A. Thus; K. Westinga; M. Plantinga; M. Bierings; A. E. C. Broers; M. L. H. Cuijpers; G. W. van Imhoff; J. J. Janssen; C. Huisman; S. Zeerleder; G. Huls; J. J. Boelens; N. M. Wulffraat; I. C. M. Slaper-Cortenbach; J. Kuball

doi:10.1038/leu.2015.89

Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells

L. C. J. te Boome, C. Mansilla, L. E. van der Wagen, C. A. Lindemans, E. J. Petersen, E. Spierings, K. A. Thus, K. Westinga, M. Plantinga, M. Bierings, A. E. C. Broers, M. L. H. Cuijpers, G. W. van Imhoff, J. J. Janssen, C. Huisman, S. Zeerleder, G. Huls, J. J. Boelens, N. M. Wulffraat, I. C. M. Slaper-CortenbachJ. Kuball^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

62 Citations (Scopus)

Abstract

We performed a prospective phase II study to evaluate clinical safety and outcome in 48 patients with steroid-refractory grade II-IV acute graft-versus-host disease (aGVHD) treated with mesenchymal stromal cells (MSCs). Clinical outcomes were correlated to comprehensive analyses of soluble and cellular biomarkers. Complete resolution (CR) of aGVHD at day 28 (CR-28) occurred in 12 (25%) patients, CR lasting 41 month (CR-B) occurred in 24 (50%) patients. One-year overall survival was significantly improved in CR-28 (75 versus 33%, P = 0.020) and CR-B (79 versus 8%, P

Original language	English
Pages (from-to)	1839-1846
Number of pages	8
Journal	Leukemia
Volume	29
Issue number	9
DOIs	https://doi.org/10.1038/leu.2015.89
Publication status	Published - Sept-2015

Keywords

VERSUS-HOST-DISEASE
CLINICAL-TRIALS NETWORK
STEM-CELLS
DENDRITIC CELLS
REFRACTORY ACUTE
IN-VIVO
LYMPHOCYTE-PROLIFERATION
PEDIATRIC-PATIENTS
PHASE I/II
THERAPY

Access to Document

10.1038/leu.2015.89

Handle.net

Persistent link

Embargoed Document

Biomarker profiling of steroid-resistant acute GVHD in patients
Final publisher's version, 400 KB
Request copy

Cite this

te Boome, L. C. J., Mansilla, C., van der Wagen, L. E., Lindemans, C. A., Petersen, E. J., Spierings, E., Thus, K. A., Westinga, K., Plantinga, M., Bierings, M., Broers, A. E. C., Cuijpers, M. L. H., van Imhoff, G. W., Janssen, J. J., Huisman, C., Zeerleder, S., Huls, G., Boelens, J. J., Wulffraat, N. M., ... Kuball, J. (2015). Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. Leukemia, 29(9), 1839-1846. https://doi.org/10.1038/leu.2015.89

@article{1f8223afe5f440059e3419bb9ee7dce8,

title = "Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells",

abstract = "We performed a prospective phase II study to evaluate clinical safety and outcome in 48 patients with steroid-refractory grade II-IV acute graft-versus-host disease (aGVHD) treated with mesenchymal stromal cells (MSCs). Clinical outcomes were correlated to comprehensive analyses of soluble and cellular biomarkers. Complete resolution (CR) of aGVHD at day 28 (CR-28) occurred in 12 (25%) patients, CR lasting 41 month (CR-B) occurred in 24 (50%) patients. One-year overall survival was significantly improved in CR-28 (75 versus 33%, P = 0.020) and CR-B (79 versus 8%, P",

keywords = "VERSUS-HOST-DISEASE, CLINICAL-TRIALS NETWORK, STEM-CELLS, DENDRITIC CELLS, REFRACTORY ACUTE, IN-VIVO, LYMPHOCYTE-PROLIFERATION, PEDIATRIC-PATIENTS, PHASE I/II, THERAPY",

author = "{te Boome}, {L. C. J.} and C. Mansilla and {van der Wagen}, {L. E.} and Lindemans, {C. A.} and Petersen, {E. J.} and E. Spierings and Thus, {K. A.} and K. Westinga and M. Plantinga and M. Bierings and Broers, {A. E. C.} and Cuijpers, {M. L. H.} and {van Imhoff}, {G. W.} and Janssen, {J. J.} and C. Huisman and S. Zeerleder and G. Huls and Boelens, {J. J.} and Wulffraat, {N. M.} and Slaper-Cortenbach, {I. C. M.} and J. Kuball",

year = "2015",

month = sep,

doi = "10.1038/leu.2015.89",

language = "English",

volume = "29",

pages = "1839--1846",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "9",

}

te Boome, LCJ, Mansilla, C, van der Wagen, LE, Lindemans, CA, Petersen, EJ, Spierings, E, Thus, KA, Westinga, K, Plantinga, M, Bierings, M, Broers, AEC, Cuijpers, MLH, van Imhoff, GW, Janssen, JJ, Huisman, C, Zeerleder, S, Huls, G, Boelens, JJ, Wulffraat, NM, Slaper-Cortenbach, ICM & Kuball, J 2015, 'Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells', Leukemia, vol. 29, no. 9, pp. 1839-1846. https://doi.org/10.1038/leu.2015.89

TY - JOUR

T1 - Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells

AU - te Boome, L. C. J.

AU - Mansilla, C.

AU - van der Wagen, L. E.

AU - Lindemans, C. A.

AU - Petersen, E. J.

AU - Spierings, E.

AU - Thus, K. A.

AU - Westinga, K.

AU - Plantinga, M.

AU - Bierings, M.

AU - Broers, A. E. C.

AU - Cuijpers, M. L. H.

AU - van Imhoff, G. W.

AU - Janssen, J. J.

AU - Huisman, C.

AU - Zeerleder, S.

AU - Huls, G.

AU - Boelens, J. J.

AU - Wulffraat, N. M.

AU - Slaper-Cortenbach, I. C. M.

AU - Kuball, J.

PY - 2015/9

Y1 - 2015/9

N2 - We performed a prospective phase II study to evaluate clinical safety and outcome in 48 patients with steroid-refractory grade II-IV acute graft-versus-host disease (aGVHD) treated with mesenchymal stromal cells (MSCs). Clinical outcomes were correlated to comprehensive analyses of soluble and cellular biomarkers. Complete resolution (CR) of aGVHD at day 28 (CR-28) occurred in 12 (25%) patients, CR lasting 41 month (CR-B) occurred in 24 (50%) patients. One-year overall survival was significantly improved in CR-28 (75 versus 33%, P = 0.020) and CR-B (79 versus 8%, P

AB - We performed a prospective phase II study to evaluate clinical safety and outcome in 48 patients with steroid-refractory grade II-IV acute graft-versus-host disease (aGVHD) treated with mesenchymal stromal cells (MSCs). Clinical outcomes were correlated to comprehensive analyses of soluble and cellular biomarkers. Complete resolution (CR) of aGVHD at day 28 (CR-28) occurred in 12 (25%) patients, CR lasting 41 month (CR-B) occurred in 24 (50%) patients. One-year overall survival was significantly improved in CR-28 (75 versus 33%, P = 0.020) and CR-B (79 versus 8%, P

KW - VERSUS-HOST-DISEASE

KW - CLINICAL-TRIALS NETWORK

KW - STEM-CELLS

KW - DENDRITIC CELLS

KW - REFRACTORY ACUTE

KW - IN-VIVO

KW - LYMPHOCYTE-PROLIFERATION

KW - PEDIATRIC-PATIENTS

KW - PHASE I/II

KW - THERAPY

U2 - 10.1038/leu.2015.89

DO - 10.1038/leu.2015.89

M3 - Article

SN - 0887-6924

VL - 29

SP - 1839

EP - 1846

JO - Leukemia

JF - Leukemia

IS - 9

ER -

Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this